BAX * Stock Overview
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$687.31 |
| 52 Week High | US$820.00 |
| 52 Week Low | US$687.31 |
| Beta | 0.63 |
| 1 Month Change | -1.60% |
| 3 Month Change | n/a |
| 1 Year Change | -11.31% |
| 3 Year Change | -60.26% |
| 5 Year Change | -53.09% |
| Change since IPO | -2.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAX * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -11.3% | 0% | 0% |
Return vs Industry: BAX * underperformed the MX Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: BAX * underperformed the MX Market which returned 1.2% over the past year.
Price Volatility
| BAX * volatility | |
|---|---|
| BAX * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BAX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BAX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 60,000 | Joe Almeida | www.baxter.com |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Baxter International Inc. Fundamentals Summary
| BAX * fundamental statistics | |
|---|---|
| Market cap | Mex$342.29b |
| Earnings (TTM) | -Mex$1.29b |
| Revenue (TTM) | Mex$251.57b |
1.4x
P/S Ratio-264.9x
P/E RatioIs BAX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAX * income statement (TTM) | |
|---|---|
| Revenue | US$14.81b |
| Cost of Revenue | US$9.15b |
| Gross Profit | US$5.66b |
| Other Expenses | US$5.74b |
| Earnings | -US$76.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 38.22% |
| Net Profit Margin | -0.51% |
| Debt/Equity Ratio | 162.1% |
How did BAX * perform over the long term?
See historical performance and comparison